Date: Mar 13, 2013 Source: Business Wire (
click here to go to the source)
Evogen is pleased to announce that it has entered into a non-exclusive License Agreement with Focus Diagnostics granting worldwide rights to incorporate Evogen proprietary and novel HyBeacons® PCR probe technology into their molecular diagnostic products and services. Focus Diagnostics, a leading molecular diagnostics company specializing in infectious disease testing, is a business of Quest Diagnostics, the world’s leading provider of diagnostic information services. Additional terms of the Agreement were not disclosed.
“We are pleased that Focus Diagnostics has chosen to incorporate the Evogen HyBeacons probe technology into their molecular diagnostic offerings. This Agreement highlights the continued evolution of HyBeacons probe technology into an industry standard”
HyBeacons probes are sequence specific hybridization probes containing two fluorophores per probe thereby creating a robust fluorescent signal. Since HyBeacons are not hydrolyzed during PCR amplification, positive confirmation of the amplicon is available by way of high definition melt curve analysis. HyBeacons are easy to design which offers the ability to multiplex different color probes for the identification of multiple targets in a single reaction. HyBeacons provide clear quantitative data during amplification and have proven capabilities with DNA and RNA targets.
“We are pleased that Focus Diagnostics has chosen to incorporate the Evogen HyBeacons probe technology into their molecular diagnostic offerings. This Agreement highlights the continued evolution of HyBeacons probe technology into an industry standard,” said Hans Kastensmith, President and CEO, Evogen, Inc.
Focus Diagnostics develops and manufactures the Simplexa line of award-winning molecular test products, operating on the 3M Integrated Cycler, for aiding in the diagnosis of influenza, Clostridium difficile, Epstein Barr and other diseases.
About Evogen, Inc
Evogen meets the molecular diagnostic collection and detection needs of a diverse range of customers. The Evogen portfolio includes DNA extraction methodologies, air collection and monitoring and proprietary PCR probe technology providing reliable, sensitive and specific answers. Through analysis of the specific needs of each customer, Evogen delivers systems and solutions that provide rapid results while lessening laboratory workflow impact. Visit www.Evogen.com.